Eupraxia Pharmaceuticals Inc. (EPRX)
NASDAQ: EPRX · Real-Time Price · USD
7.11
-0.10 (-1.39%)
At close: Apr 28, 2026, 4:00 PM EDT
7.32
+0.21 (2.95%)
After-hours: Apr 28, 2026, 7:08 PM EDT
Eupraxia Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Selling, General & Admin | 17.1 | 10.92 | 7.48 | 3.99 | 6.48 | |
| Research & Development | 21.33 | 16.08 | 20.36 | 13.63 | 7.58 | |
| Operating Expenses | 38.43 | 27 | 27.85 | 17.62 | 14.15 | |
| Operating Income | -38.43 | -27 | -27.85 | -17.62 | -14.15 | |
| Interest Expense | - | -0.96 | -1.17 | -0.98 | -0.97 | |
| Interest & Investment Income | 1.41 | 1.16 | 0.86 | 0.43 | 0.05 | |
| Currency Exchange Gain (Loss) | -1.56 | -0.16 | 0.07 | 0.24 | 0.16 | |
| Other Non Operating Income (Expenses) | - | 1.2 | -0.84 | -1.06 | -4.74 | |
| EBT Excluding Unusual Items | -38.58 | -25.76 | -28.92 | -18.98 | -19.65 | |
| Gain (Loss) on Sale of Assets | -0 | 0.02 | -0 | -0.01 | - | |
| Other Unusual Items | - | - | - | - | 0.42 | |
| Pretax Income | -38.59 | -25.74 | -28.93 | -18.99 | -19.23 | |
| Income Tax Expense | 0.02 | 0 | 0.04 | - | - | |
| Earnings From Continuing Operations | -38.61 | -25.74 | -28.97 | -18.99 | -19.23 | |
| Minority Interest in Earnings | 0.03 | 0.24 | 0.75 | 0.5 | 0.3 | |
| Net Income | -38.58 | -25.5 | -28.22 | -18.49 | -18.93 | |
| Preferred Dividends & Other Adjustments | 2.53 | 0.43 | - | - | - | |
| Net Income to Common | -41.11 | -25.93 | -28.22 | -18.49 | -18.93 | |
| Shares Outstanding (Basic) | 40 | 34 | 24 | 19 | 12 | |
| Shares Outstanding (Diluted) | 40 | 34 | 24 | 19 | 12 | |
| Shares Change (YoY) | 17.76% | 40.52% | 25.21% | 55.45% | 102.75% | |
| EPS (Basic) | -1.03 | -0.76 | -1.17 | -0.96 | -1.53 | |
| EPS (Diluted) | -1.03 | -0.76 | -1.17 | -0.96 | -1.53 | |
| Free Cash Flow | -29.14 | -30.1 | -20.82 | -14.63 | -12.06 | |
| Free Cash Flow Per Share | -0.73 | -0.89 | -0.86 | -0.76 | -0.97 | |
| EBITDA | -38.27 | -26.89 | -27.73 | -17.51 | -14.11 | |
| D&A For EBITDA | 0.16 | 0.11 | 0.11 | 0.11 | 0.04 | |
| EBIT | -38.43 | -27 | -27.85 | -17.62 | -14.15 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.